Contineum Therapeutics, Inc. (CTNM)
Market Cap | 540.19M |
Revenue (ttm) | 50.00M |
Net Income (ttm) | -447,000 |
Shares Out | 25.72M |
EPS (ttm) | -0.02 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 31,089 |
Open | 21.24 |
Previous Close | 21.05 |
Day's Range | 20.75 - 21.24 |
52-Week Range | 13.27 - 22.00 |
Beta | n/a |
Analysts | Strong Buy |
Price Target | 28.00 (+33.33%) |
Earnings Date | Aug 16, 2024 |
About CTNM
Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS). The company also develops PIPE-307, a novel, small molecule selective inhibitor of the muscarinic type... [Read more]
Analyst Forecast
According to 3 analysts, the average rating for CTNM stock is "Strong Buy." The 12-month stock price forecast is $28.0, which is an increase of 33.33% from the latest price.
News
Contineum Therapeutics Announces Appointment of Sarah Boyce to Board of Directors
SAN DIEGO--(BUSINESS WIRE)--Contineum Therapeutics, Inc. (Nasdaq: CTNM), a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies that targ...
Contineum Therapeutics to Present at the 45th Annual Goldman Sachs Healthcare Conference
SAN DIEGO--(BUSINESS WIRE)--Contineum Therapeutics, Inc. (Nasdaq: CTNM), a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies that targ...
Contineum Therapeutics Announces Appointment of John Healy as General Counsel & Corporate Secretary
SAN DIEGO--(BUSINESS WIRE)--Contineum Therapeutics, Inc. (Nasdaq: CTNM), a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies that targ...
Contineum Therapeutics Announces Appointment of Troy Ignelzi to Board of Directors
SAN DIEGO--(BUSINESS WIRE)--Contineum Therapeutics, Inc. (Nasdaq: CTNM), a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies that targ...
Contineum Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights
SAN DIEGO--(BUSINESS WIRE)--Contineum Therapeutics, Inc. (Nasdaq: CTNM), a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies that targ...
Contineum Therapeutics Announces Pricing of Initial Public Offering
SAN DIEGO, April 04, 2024 (GLOBE NEWSWIRE) -- Contineum Therapeutics, Inc. (Contineum), a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule ther...
Neuroscience and inflammation biotech Contineum Therapeutics files for a $150 million IPO
Contineum Therapeutics, a Phase 1 biotech developing small molecule therapies for NI&I indications, filed on Friday with the SEC to raise up to $150 million in an initial public offering.
Contineum Therapeutics IPO Registration Document (S-1)
Contineum Therapeutics has filed to go public with an IPO on the NASDAQ.